
PRECISION MEDICINE

precision medicine has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve and precision medicine and biomarkers will transform the delivery of cancer care to benefit both patients and cancer care systems.
the european commission defined [2015] personalised medicine as “a model of medicine that uses the molecular profile [phenotypes and genotypes] for tailoring the right therapeutic strategy for the right person at the right time, and | or to determine the predisposition to disease and | or to deliver timely and targeted prevention” working in collaboration, we can greatly improve access to precision medicines and biomarkers, with a flexible regulatory framework that accelerates access, encouraging policies that invest in and support the use of precision medicines and biomarkers, and educating on the potential effectiveness and efficiency precision medicine and biomarkers can make in our health care system.
precision medicine is rapidly having an impact on how drugs are discovered and developed; how patients are diagnosed and treated; and how health care delivery is channeling its resources to maximize patient benefits. precision medicine is having an important impact in clinical care, the great potential to improve the quality of patient care and to help contain health care costs and it should be directed at individual patients through the practice of medicine rather than through regulatory action.


#CRACKINGTHECANCERCODE
montréal. november 2. 2020– throughout the month of november, the cancer collaborative in collaboration with the european cancer patients coalition [ECPC] will highlight the growing role that precision medicine plays in oncology through the CRACKING THE CANCER CODE campaign.

what are biomarkers
understanding cancer - cancer is a disease that is characterized by abnormal cell process involving uncontrolled cell growth and proliferation that alters normal cell behaviour. the genetic alterations within the cancer cells will be manifested by the release of...
precision medicine awareness month launches in canada
throughout the month of november, the cancer collaborative in collaboration with the european cancer patients coalition [ECPC] will highlight the growing role that precision medicine plays in oncology through the CRACKING THE CANCER CODE campaign. the premise of...
#travelwithcolab
this year promises to be another filled with interesting conversations, dynamic dialogues and learning, lots of learning - across the globe. learning from different experiences, various perspectives, understanding how things are done outside of canada and taking those...
ASCO 2020 clinical advances of the year
ASCO has published their annual report on progress against cancer - the report highlights the most important clinical research advances of the past year and identifies priority areas where ASCO believes research efforts should focus moving forward. this year the...
the future of healthcare is personalized.
rapid advances of the molecular pathways that underlie cancer combined with an expansion of the tools at our disposal to diagnose and treat based on these specific genomic features has paved the way for precision medicine in cancer and other diseases. and as we...
understanding cancer
cancer is a collection of related diseases that can occur almost anywhere in the body and is characterized by abnormal cell process involving uncontrolled cell growth and proliferation that alters normal cell behaviour. there are over 100 types of cancers, and in all...
car-t. hype or hope
a few weeks ago, I attended the canadian agency for drugs and technologies in health [CADTH] symposium in edmonton, AB. the opening plenary discussion was on 'the hope and hype' in healthcare. your perspective on this, of course, depends on how you’re looking at...
challenges & potential barriers to access
with recent health canada approvals of two new car-t cell treatments [tisagenlecleucel in september 2018 and [axicabtagene ciloleuce] in february 2019], canada is slowly starting to join the car-t club [at this time car-t has been approved in the USA and the UK]....
IEEPO recap- further thoughts on the promise of personalised medicine
last week i had the opportunity to attend the international experience exchange for patient organizations [IEEPO] in rome, italy. the theme — "personalised healthcare- what’s in for patients" explored topics like digital health interventions, data collection and...
the promise of personalized medicine
personalised medicine is widely considered as the way of the future for medicine, especially in cancer, where we are moving away from the one size fits all, trial and error model towards a more tailored, personalized approach. and this has the potential to change the...